U.S., July 24 -- ClinicalTrials.gov registry received information related to the study (NCT07079735) titled 'Valganciclovir vs. Letermovir for CMV Prophylaxis in Heart Transplant' on July 09.
Brief Summary: The purpose of this study is to compare the safety and efficacy of letermovir with valganciclovir for prevention of Cytomegalovirus (CMV) viremia in moderate to high risk serostatus heart transplant recipients.
Study Start Date: Aug. 17
Study Type: INTERVENTIONAL
Condition:
CMV Viremia
Heart Transplant Infection
Heart Transplant Failure and Rejection
Intervention:
DRUG: Letermovir
CMV prophylaxis
DRUG: Valganciclovir
Standard therapy for CMV prophylaxis
Recruitment Status: RECRUITING
Sponsor: Columbia University
Information ...